胰高血糖素样肽-1受体激动剂与甲状腺癌：是时候引起关注了吗？
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
作者信息
Lisco Giuseppe, De Tullio Anna, Disoteo Olga, Piazzolla Giuseppina, Guastamacchia Edoardo, Sabbà Carlo, De Geronimo Vincenzo, Papini Enrico, Triggiani Vincenzo
机构信息
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari "Aldo Moro", Piazza Giulio Cesare, Bari, Italy.
Diabetology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
出版信息
Endocr Connect. 2023 Sep 27;12(11). doi: 10.1530/EC-23-0257. Print 2023 Nov 1.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.
摘要
胰高血糖素样肽-1受体激动剂（GLP-1RAs）极大地改变了2型糖尿病（T2D）的治疗方式。然而，近期发表的回顾性队列研究数据表明，T2D患者长期使用GLP-1RAs可能会增加甲状腺乳头状癌和髓样癌的风险。从这一角度出发，对肠促胰岛素系统在甲状腺癌发生中的作用进行了综述并给出了批判性评论，旨在了解是否到了该关注这一风险的时候。尽管有证据表明，但推测性假设仍需验证，迫切需要进一步研究来阐明这一问题。
相似文献
1
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Endocr Connect. 2023 Sep 27;12(11). doi: 10.1530/EC-23-0257. Print 2023 Nov 1.
2
Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Postgrad Med. 2021 Nov;133(8):843-853. doi: 10.1080/00325481.2021.1971461. Epub 2021 Sep 12.
3
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Postgrad Med. 2020 Nov;132(sup2):3-14. doi: 10.1080/00325481.2020.1798099. Epub 2020 Sep 8.
4
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5.
5
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
Pharmacol Ther. 2022 Nov;239:108277. doi: 10.1016/j.pharmthera.2022.108277. Epub 2022 Sep 3.
6
Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.
Endocr Pract. 2013 Jul-Aug;19(4):718-28. doi: 10.4158/EP12292.RA.
7
An updated review on cancer risk associated with incretin mimetics and enhancers.
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(1):67-124. doi: 10.1080/10590501.2015.1003496.
8
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
9
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
10
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Cardiovasc Diabetol. 2018 Jul 17;17(1):102. doi: 10.1186/s12933-018-0746-4.
引用本文的文献
1
The Impact and Safety of GLP-1 Agents and Breast Cancer.
Cancer Med. 2025 Jun;14(12):e70932. doi: 10.1002/cam4.70932.
2
Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis.
Ther Adv Drug Saf. 2025 Apr 21;16:20420986251335214. doi: 10.1177/20420986251335214. eCollection 2025.
3
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions.
Rev Endocr Metab Disord. 2025 Apr 2. doi: 10.1007/s11154-025-09958-5.
4
Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence.
Biomark Res. 2025 Mar 27;13(1):50. doi: 10.1186/s40364-025-00765-3.
5
Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.
Endocrinol Diabetes Metab. 2025 Mar;8(2):e70038. doi: 10.1002/edm2.70038.
6
Anti-Diabetic Therapies and Cancer: From Bench to Bedside.
Biomolecules. 2024 Nov 20;14(11):1479. doi: 10.3390/biom14111479.
7
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.
Medicine (Baltimore). 2024 Nov 1;103(44):e40364. doi: 10.1097/MD.0000000000040364.
8
A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?
Surg Endosc. 2024 Nov;38(11):6560-6565. doi: 10.1007/s00464-024-11191-1. Epub 2024 Sep 16.
9
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.
Cancers (Basel). 2024 Apr 23;16(9):1625. doi: 10.3390/cancers16091625.
本文引用的文献
1
Obesity and thyroid cancer risk.
Curr Opin Endocrinol Diabetes Obes. 2023 Oct 1;30(5):244-251. doi: 10.1097/MED.0000000000000825. Epub 2023 Jul 6.
2
Thyroid Nodules and Obesity.
Life (Basel). 2023 May 31;13(6):1292. doi: 10.3390/life13061292.
3
Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism.
Discov Oncol. 2023 Feb 22;14(1):23. doi: 10.1007/s12672-022-00599-7.
4
Adipose tissue macrophages: implications for obesity-associated cancer.
Mil Med Res. 2023 Jan 3;10(1):1. doi: 10.1186/s40779-022-00437-5.
5
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Front Endocrinol (Lausanne). 2022 Dec 7;13:1043789. doi: 10.3389/fendo.2022.1043789. eCollection 2022.
6
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts.
Diabetes Care. 2023 Feb 1;46(2):249-251. doi: 10.2337/dci22-0052.
7
GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
Front Pharmacol. 2022 Oct 25;13:925377. doi: 10.3389/fphar.2022.925377. eCollection 2022.
8
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
Nutrients. 2022 Nov 4;14(21):4673. doi: 10.3390/nu14214673.
9
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
Diabetes Care. 2023 Feb 1;46(2):384-390. doi: 10.2337/dc22-1148.
10
Dipeptidyl Peptidase-4 Stabilizes Integrin α4β1 Complex to Promote Thyroid Cancer Cell Metastasis by Activating Transforming Growth Factor-Beta Signaling Pathway.
Thyroid. 2022 Nov;32(11):1411-1422. doi: 10.1089/thy.2022.0317.
Zotero 插件